Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

The RIETE Investigators

doi:10.1007/s11739-021-02858-x

Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

The RIETE Investigators

Bar-Ilan University - Azrieli Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10–2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04–2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.

Original language	English
Pages (from-to)	725-734
Number of pages	10
Journal	Internal and Emergency Medicine
Volume	17
Issue number	3
DOIs	https://doi.org/10.1007/s11739-021-02858-x
State	Published - 1 Apr 2022

Bibliographical note

Publisher Copyright:
© 2021, Società Italiana di Medicina Interna (SIMI).

Funding

We express our gratitude to Sanofi Spain, LEO PHARMA and ROVI for supporting this Registry with an unrestricted educational grant. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support. MD Adarraga, J Aibar, J Alonso, C Amado, JI Arcelus, A Asuero, A Ballaz, R Barba, C Barbagelata, M Barrón, B Barrón-Andrés, A Blanco-Molina, F Beddar Chaib, E Botella, J Castro, L Chasco, J Criado, C de Ancos, J del Toro, P Demelo-Rodríguez, AM Díaz-Brasero, MC Díaz-Pedroche, JA Díaz-Peromingo, MV Di Campli, A Dubois-Silva, JC Escribano, F Espósito, AI Farfán-Sedano, C Fernández-Capitán, JL Fernández-Reyes, MA Fidalgo, K Flores, C Font, L Font, I Francisco, C Gabara, F Galeano-Valle, MA García, F García-Bragado, M García de Herreros, RG de la Garza, C García-Díaz, A Gil-Díaz, C Gómez-Cuervo, E Grau, L Guirado, J Gutiérrez, L Hernández-Blasco, L Jara-Palomares, MJ Jaras, D Jiménez, R Jiménez, C Jiménez-Alfaro, MD Joya, S Lainez-Justo, A Lalueza, A Latorre, J Lima, JL Lobo, L López-Jiménez, P López-Miguel, JJ López-Núñez, R López-Reyes, JB López-Sáez, A Lorenzo, O Madridano, A Maestre, PJ Marchena, M Martín del Pozo, F Martín-Martos, D Martínez-Urbistondo, C Mella, MI Mercado, J Moisés, M Monreal, A Muñoz-Blanco, JA Nieto, E Nofuentes-Pérez, MJ Núñez-Fernández, M Olid-Velilla, MC Olivares, J Osorio, S Otalora, R Otero, D Paredes, JM Pedrajas, JA Porras, J Portillo, I Redondo, C Rodríguez-Matute, V Rosa, P Ruiz-Artacho, J Ruiz-Ruiz, G Salgueiro, R Sánchez-Martínez, JF Sánchez-Muñoz-Torrero, T Sancho, S Soler, B Suárez-Rodríguez, JM Suriñach, MI Torres, A Torres-Sánchez, C Tolosa, J Trujillo-Santos, F Uresandi, B Valero, R Valle, JF Varona, L Vela, JR Vela, G Vidal, A Villalobos, P Villares, C Zamora, C Ay, S Nopp, I Pabinger, MM Engelen, T Vanassche , P Verhamme, J Hirmerova, R Malý, S Accassat, N Ait Abdallah, L Bertoletti, A Bura-Riviere, J Catella, F Couturaud, B Crichi, P Debourdeau, O Espitia, D Farge-Bancel, C Grange, H Helfer, K Lacut, R Le Mao, I Mahé , P Morange, F Moustafa, G Poenou, G Sarlon-Bartoli, P Suchon, I Quere, S Schellong, A Braester, B Brenner, G Kenet, I Tzoran, M Basaglia, F Bilora, C Bortoluzzi, B Brandolin, M Ciammaichella, A De Angelis, P Di Micco , E Imbalzano, S Merla, R Pesavento, P Prandoni, C Siniscalchi, A Tufano A, A Visonà, N Vo Hong, B Zalunardo , Y Nishimoto, Y Sato, K Make, A Skride, S Strautmane, S Fonseca, F Martins, J Meireles, M Bosevski, H Bounameaux, L Mazzolai, JA Caprini, HM Bui.

Funders	Funder number
D Farge-Bancel
F Galeano-Valle
F Martín-Martos
S&H Medical Science Service

Keywords

Anticoagulation adverse events
Clinical VTE
Healthy individuals
Non-invasive liver assessment
VTE risk assessment

Access to Document

10.1007/s11739-021-02858-x

Cite this

@article{7330aed3ab934464907f01334608c2c8,

title = "Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism",

abstract = "The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmb{\'o}lica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10–2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04–2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.",

keywords = "Anticoagulation adverse events, Clinical VTE, Healthy individuals, Non-invasive liver assessment, VTE risk assessment",

author = "{The RIETE Investigators} and Diego Mart{\'i}nez-Urbistondo and {de la Garza}, {Roc{\'i}o G.} and Paula Villares-Fern{\'a}ndez and Carme Font and Sebastian Schellong and L{\'o}pez-N{\'u}{\~n}ez, {Juan Jos{\'e}} and A{\'i}da Gil-D{\'i}az and {del Carmen D{\'i}az-Pedroche}, Mar{\'i}a and Jana Hirmerova and Manuel Monreal and Md Adarraga and J. Aibar and J. Alonso and C. Amado and Ji Arcelus and A. Asuero and A. Ballaz and R. Barba and C. Barbagelata and M. Barr{\'o}n and B. Barr{\'o}n-Andr{\'e}s and A. Blanco-Molina and {Beddar Chaib}, F. and E. Botella and J. Castro and L. Chasco and J. Criado and {de Ancos}, C. and {del Toro}, J. and P. Demelo-Rodr{\'i}guez and Am D{\'i}az-Brasero and Ja D{\'i}az-Peromingo and {Di Campli}, Mv and A. Dubois-Silva and Jc Escribano and F. Esp{\'o}sito and Ai Farf{\'a}n-Sedano and C. Fern{\'a}ndez-Capit{\'a}n and Jl Fern{\'a}ndez-Reyes and Ma Fidalgo and K. Flores and C. Font and L. Font and I. Francisco and C. Gabara and F. Galeano-Valle and Ma Garc{\'i}a and F. Garc{\'i}a-Bragado and {Garc{\'i}a de Herreros}, M. and A. Braester",

note = "Publisher Copyright: {\textcopyright} 2021, Societ{\`a} Italiana di Medicina Interna (SIMI).",

year = "2022",

month = apr,

day = "1",

doi = "10.1007/s11739-021-02858-x",

language = "אנגלית",

volume = "17",

pages = "725--734",

journal = "Internal and Emergency Medicine",

issn = "1828-0447",

publisher = "Springer-Verlag Italia",

number = "3",

}

TY - JOUR

T1 - Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

AU - The RIETE Investigators

AU - Martínez-Urbistondo, Diego

AU - de la Garza, Rocío G.

AU - Villares-Fernández, Paula

AU - Font, Carme

AU - Schellong, Sebastian

AU - López-Núñez, Juan José

AU - Gil-Díaz, Aída

AU - del Carmen Díaz-Pedroche, María

AU - Hirmerova, Jana

AU - Monreal, Manuel

AU - Adarraga, Md

AU - Aibar, J.

AU - Alonso, J.

AU - Amado, C.

AU - Arcelus, Ji

AU - Asuero, A.

AU - Ballaz, A.

AU - Barba, R.

AU - Barbagelata, C.

AU - Barrón, M.

AU - Barrón-Andrés, B.

AU - Blanco-Molina, A.

AU - Beddar Chaib, F.

AU - Botella, E.

AU - Castro, J.

AU - Chasco, L.

AU - Criado, J.

AU - de Ancos, C.

AU - del Toro, J.

AU - Demelo-Rodríguez, P.

AU - Díaz-Brasero, Am

AU - Díaz-Peromingo, Ja

AU - Di Campli, Mv

AU - Dubois-Silva, A.

AU - Escribano, Jc

AU - Espósito, F.

AU - Farfán-Sedano, Ai

AU - Fernández-Capitán, C.

AU - Fernández-Reyes, Jl

AU - Fidalgo, Ma

AU - Flores, K.

AU - Font, C.

AU - Font, L.

AU - Francisco, I.

AU - Gabara, C.

AU - Galeano-Valle, F.

AU - García, Ma

AU - García-Bragado, F.

AU - García de Herreros, M.

AU - Braester, A.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10–2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04–2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.

AB - The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10–2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04–2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.

KW - Anticoagulation adverse events

KW - Clinical VTE

KW - Healthy individuals

KW - Non-invasive liver assessment

KW - VTE risk assessment

UR - http://www.scopus.com/inward/record.url?scp=85116816148&partnerID=8YFLogxK

U2 - 10.1007/s11739-021-02858-x

DO - 10.1007/s11739-021-02858-x

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34626318

AN - SCOPUS:85116816148

SN - 1828-0447

VL - 17

SP - 725

EP - 734

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

IS - 3

ER -

Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this